These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

685 related items for PubMed ID: 8680052

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.
    Moreso F, Serón D, Morales JM, Cruzado JM, Gil-Vernet S, Pérez JL, Fulladosa X, Andrés A, Grinyó JM.
    Clin Transplant; 1998 Jun; 12(3):198-205. PubMed ID: 9642510
    [Abstract] [Full Text] [Related]

  • 3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 4. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.
    Hebert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, Roberts JP.
    Transplantation; 1999 Mar 15; 67(5):707-12. PubMed ID: 10096526
    [Abstract] [Full Text] [Related]

  • 5. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    J Surg Res; 2007 Apr 15; 138(2):198-204. PubMed ID: 17292404
    [Abstract] [Full Text] [Related]

  • 6. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia.
    Hao C, Anwei M, Bing C, Baiyong S, Weixia Z, Chuan S, Erzhen C, Xiaxing D, Weihua Q, Weiping Y, Chenghong P, Hongwei L.
    Liver Transpl; 2008 Aug 15; 14(8):1165-73. PubMed ID: 18668650
    [Abstract] [Full Text] [Related]

  • 7. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.
    Clin Chem; 2001 Jan 15; 47(1):88-94. PubMed ID: 11148182
    [Abstract] [Full Text] [Related]

  • 8. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr 15; 61(7):1029-37. PubMed ID: 8623181
    [Abstract] [Full Text] [Related]

  • 9. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ.
    Transplantation; 1999 Jul 27; 68(2):261-6. PubMed ID: 10440399
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
    Langrehr JM, Klupp J, Glanemann M, Junge G, Pfitzmann R, Bahra M, Radtke C, Neumann U, Neuhaus R, Neuhaus P.
    Clin Transplant; 2006 Jul 27; 20(3):272-83. PubMed ID: 16824141
    [Abstract] [Full Text] [Related]

  • 13. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, Rama I, Torras J.
    Transpl Int; 2003 Nov 27; 16(11):820-7. PubMed ID: 12879230
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of mycophenolate mofetil on recurrent rejection in kidney transplant patients.
    Vasquez EM, Sifontis NM, Pollak R, Benedetti E.
    Clin Transplant; 2001 Aug 27; 15(4):253-7. PubMed ID: 11683819
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, Shiffman ML, Luketic VA, Contos MJ, Mills AS, Ferreira-Gonzalez A, Posner MP.
    Clin Transplant; 2004 Aug 27; 18(4):463-72. PubMed ID: 15233827
    [Abstract] [Full Text] [Related]

  • 18. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis.
    Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT.
    Liver Transpl Surg; 1999 Sep 27; 5(5):375-80. PubMed ID: 10477838
    [Abstract] [Full Text] [Related]

  • 19. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F, Pruv FR, Noël C.
    J Am Soc Nephrol; 2005 Aug 27; 16(8):2509-16. PubMed ID: 15987748
    [Abstract] [Full Text] [Related]

  • 20. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Bergougnoux L, Touchard G.
    Nephrol Dial Transplant; 2008 Jun 27; 23(6):2024-32. PubMed ID: 18199693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.